Brian R Baer

Publication Activity (10 Years)

Years Active: 2024-2024
Publications (10 Years): 4

This page only lists publications with an associated author ORCID identifier.

Publications

Li Ren, David Moreno, Brian R Baer, Patrick Barbour, Tanna Bettendorf, Karyn Bouhana, Karin Brown, Suzy A Brown, Jay B Fell, Dylan P Hartley, Erik J Hicken, Ellen R Laird, Patrice Lee, Joseph McCown, Jennifer N Otten, Brett Prigaro, Ross Wallace, Dean R Kahn
Identification of the Clinical Candidate PF-07284890 ( ARRY-461 ), a Highly Potent and Brain Penetrant BRAF Inhibitor for the Treatment of Cancer. Journal of medicinal chemistry 67 (15) (2024)
Li Ren, David Moreno, Brian R Baer, Patrick Barbour, Tanna Bettendorf, Karyn Bouhana, Karin Brown, Suzy A Brown, Jay B Fell, Dylan P Hartley, Erik J Hicken, Ellen R Laird, Patrice Lee, Joseph McCown, Jennifer N Otten, Brett Prigaro, Ross Wallace, Dean R Kahn
Identification of the Clinical Candidate PF-07284890 ( ARRY-461 ), a Highly Potent and Brain Penetrant BRAF Inhibitor for the Treatment of Cancer. Journal of medicinal chemistry 67 (15) (2024)
Rona Yaeger, Meredith A McKean, Rizwan Haq, J Thaddeus Beck, Matthew H Taylor, Jonathan Eliezer Cohen, Daniel W Bowles, Shirish M Gadgeel, Catalin Mihalcioiu, Kyriakos P Papadopoulos, Eli L Diamond, Keren B Sturtz, Gang Feng, Stefanie K Drescher, Micaela B Reddy, Bhaswati Sengupta, Arnab Kumar Maity, Suzy A Brown, Anurag Singh, Eric N Brown, Brian R Baer, Jim Wong, Tung-Chung Mou, Wen-I Wu, Dean R Kahn, Sunyana Gadal, Neal X Rosen, John J Gaudino, Patrice A Lee, Dylan P Hartley, S Michael Rothenberg
A next-generation BRAF inhibitor overcomes resistance to BRAF inhibition in patients with BRAF-mutant cancers using pharmacokinetics-informed dose escalation. Cancer discovery (2024)
Li Ren, David Moreno, Brian R Baer, Patrick Barbour, Tanna Bettendorf, Karyn Bouhana, Karin Brown, Suzy A Brown, Jay B Fell, Dylan P Hartley, Erik J Hicken, Ellen R Laird, Patrice Lee, Joseph McCown, Jennifer N Otten, Brett Prigaro, Ross Wallace, Dean R Kahn
Identification of the Clinical Candidate PF-07284890 ( ARRY-461 ), a Highly Potent and Brain Penetrant BRAF Inhibitor for the Treatment of Cancer. Journal of medicinal chemistry (2024)